Human Gene TTR (ENST00000237014.8_4) from GENCODE V47lift37
  Description: transthyretin (from RefSeq NM_000371.4)
Gencode Transcript: ENST00000237014.8_4
Gencode Gene: ENSG00000118271.12_15
Transcript (Including UTRs)
   Position: hg19 chr18:29,171,840-29,178,784 Size: 6,945 Total Exon Count: 4 Strand: +
Coding Region
   Position: hg19 chr18:29,171,866-29,178,638 Size: 6,773 Coding Exon Count: 4 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesGeneReviewsModel Information
Methods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr18:29,171,840-29,178,784)mRNA (may differ from genome)Protein (147 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: TTHY_HUMAN
DESCRIPTION: RecName: Full=Transthyretin; AltName: Full=ATTR; AltName: Full=Prealbumin; AltName: Full=TBPA; Flags: Precursor;
FUNCTION: Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
SUBUNIT: Homotetramer. Dimer of dimers. In the homotetramer, subunits assemble around a central channel that can accommodate two ligand molecules. Interacts with RBP4.
SUBCELLULAR LOCATION: Secreted. Cytoplasm.
TISSUE SPECIFICITY: Detected in serum and cerebrospinal fluid (at protein level). Highly expressed in choroid plexus epithelial cells. Detected in retina pigment epithelium and liver.
DOMAIN: Each monomer has two 4-stranded beta sheets and the shape of a prolate ellipsoid. Antiparallel beta-sheet interactions link monomers into dimers. A short loop from each monomer forms the main dimer-dimer interaction. These two pairs of loops separate the opposed, convex beta-sheets of the dimers to form an internal channel.
PTM: Not glycosylated under normal conditions. Following unfolding, caused for example by variant AMYL-TTR 'Gly-38', the cryptic Asn-118 site is exposed and glycosylated by STT3B- containing OST complex, leading to its degradation by the ER- associated degradation (ERAD) pathway.
DISEASE: Defects in TTR are the cause of amyloidosis transthyretin-related (AMYL-TTR) [MIM:105210]. A hereditary generalized amyloidosis due to transthyretin amyloid deposition. Protein fibrils can form in different tissues leading to amyloid polyneuropathies, amyloidotic cardiomyopathy, carpal tunnel syndrome, systemic senile amyloidosis. The disease includes leptomeningeal amyloidosis that is characterized by primary involvement of the central nervous system. Neuropathologic examination shows amyloid in the walls of leptomeningeal vessels, in pia arachnoid, and subpial deposits. Some patients also develop vitreous amyloid deposition that leads to visual impairment (oculoleptomeningeal amyloidosis). Clinical features include seizures, stroke-like episodes, dementia, psychomotor deterioration, variable amyloid deposition in the vitreous humor.
DISEASE: Defects in TTR are a cause of hyperthyroxinemia dystransthyretinemic euthyroidal (HTDE) [MIM:145680]. It is a condition characterized by elevation of total and free thyroxine in healthy, euthyroid persons without detectable binding protein abnormalities.
DISEASE: Defects in TTR are a cause of carpal tunnel syndrome type 1 (CTS1) [MIM:115430]. It is a condition characterized by entrapment of the median nerve within the carpal tunnel. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers which may radiate proximally. Impairment of sensation in the distribution of the median nerve and thenar muscle atrophy may occur. This condition may be associated with repetitive occupational trauma, wrist injuries, amyloid neuropathies, rheumatoid arthritis.
MISCELLANEOUS: Tetramer dissociation and partial unfolding leads to the formation of aggregates and amyloid fibrils. Small molecules that occupy at least one of the thyroid hormone binding sites stabilize the tetramer, and thereby stabilize the native state and protect against misfolding and the formation of amyloid fibrils.
MISCELLANEOUS: Two binding sites for thyroxine are located in the channel. Less than 1% of plasma prealbumin molecules are normally involved in thyroxine transport. L-thyroxine binds to the transthyretin by an order of magnitude stronger than does the triiodo-L-thyronine. Thyroxine-binding globulin is the major carrier protein for thyroid hormones in man.
MISCELLANEOUS: About 40% of plasma transthyretin circulates in a tight protein-protein complex with the plasma retinol-binding protein (RBP). The formation of the complex with RBP stabilizes the binding of retinol to RBP and decreases the glomerular filtration and renal catabolism of the relatively small RBP molecule. There is evidence for 2 binding sites for RBP, one possibly being a region that includes Ile-104, located on the outer surface of the transthyretin molecule.
SIMILARITY: Belongs to the transthyretin family.
WEB RESOURCE: Name=GeneReviews; URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TTR";
WEB RESOURCE: Name=Wikipedia; Note=Transthyretin entry; URL="http://en.wikipedia.org/wiki/Transthyretin";

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: TTR
Diseases sorted by gene-association score: amyloidosis, hereditary, transthyretin-related* (1718), carpal tunnel syndrome, familial* (1225), hyperthyroxinemia, dystransthyretinemic* (329), atrial standstill, digenic* (200), cardiomyopathy* (178), familial amyloid cardiomyopathy* (118), amyloidosis (85), hyperthyroxinemia (55), hereditary amyloidosis (41), leptomeningeal amyloidosis (40), polyneuropathy (29), protein-energy malnutrition (25), choroid plexus cancer (21), nutritional deficiency disease (19), decubitus ulcer (19), amyloid neuropathy (19), burns (19), familial oculoleptomeningeal amyloidosis (18), atrophic glossitis (18), restrictive cardiomyopathy (17), choroid plexus papilloma (14), hypervitaminosis a (14), phenylketonuria (13), keratomalacia (13), obstructive jaundice (12), glossitis (12), amyloidosis, finnish type (12), chronic ulcer of skin (11), dysalbuminemic hyperthyroxinemia (11), carotenemia (11), autonomic peripheral neuropathy (11), ligneous conjunctivitis (10), chronic pulmonary heart disease (10), respiratory failure (10), paramyloidosis (10), cerebral amyloid angiopathy (9), demyelinating polyneuropathy (9), chronic kidney failure (9), analbuminemia (9), nerve compression syndrome (9), dysentery (9), amyloid tumor (8), chronic inflammatory demyelinating polyneuropathy (8), amyloidosis, familial visceral (8), testicular yolk sac tumor (7), barth syndrome (7), blepharochalasis (7), peripheral nervous system disease (7), amyloidosis aa (7), marasmus (7), short bowel syndrome (6), median rhomboid glossitis (6), autonomic nervous system disease (6), tibial neuropathy (6), tarsal tunnel syndrome (6), shigellosis (6), pediatric multiple sclerosis (6), kwashiorkor (6), retinitis pigmentosa 7 and digenic (6), meningococcal infection (6), papillary ependymoma (5), molybdenum cofactor deficiency (5), sella turcica neoplasm (5), tuberculum sellae meningioma (5), pure autonomic failure (5), bladder neck obstruction (5), aleutian mink disease (4), hypertropia (4), brown-sequard syndrome (4), localized osteosarcoma (4), heart disease (2), central nervous system disease (2), hydrocephalus (2), acquired metabolic disease (2), nervous system disease (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 1516.85 RPKM in Liver
Total median expression: 1737.29 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -1.2026-0.046 Picture PostScript Text
3' UTR -33.10146-0.227 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR023418 - Thyroxine_BS
IPR000895 - Transthyretin/HIU_hydrolase
IPR023416 - Transthyretin/HIU_hydrolase_SF
IPR023419 - Transthyretin_CS

Pfam Domains:
PF00576 - HIUase/Transthyretin family

SCOP Domains:
49472 - Transthyretin (synonym: prealbumin)

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1BM7 - X-ray MuPIT 1BMZ - X-ray MuPIT 1BZ8 - X-ray MuPIT 1BZD - X-ray MuPIT 1BZE - X-ray MuPIT 1DVQ - X-ray MuPIT 1DVS - X-ray MuPIT 1DVT - X-ray MuPIT 1DVU - X-ray MuPIT 1DVX - X-ray MuPIT 1DVY - X-ray MuPIT 1DVZ - X-ray MuPIT 1E3F - X-ray 1E4H - X-ray 1E5A - X-ray 1ETA - X-ray MuPIT 1ETB - X-ray MuPIT 1F41 - X-ray MuPIT 1F64 - Model 1F86 - X-ray MuPIT 1FH2 - X-ray 1FHN - X-ray 1G1O - X-ray MuPIT 1GKO - X-ray MuPIT 1ICT - X-ray 1III - X-ray MuPIT 1IIK - X-ray MuPIT 1IJN - X-ray MuPIT 1QAB - X-ray 1QWH - X-ray MuPIT 1RLB - X-ray 1SOK - X-ray MuPIT 1SOQ - X-ray MuPIT 1THA - X-ray MuPIT 1THC - X-ray MuPIT 1TLM - X-ray MuPIT 1TSH - X-ray MuPIT 1TT6 - X-ray MuPIT 1TTA - X-ray MuPIT 1TTB - X-ray MuPIT 1TTC - X-ray MuPIT 1TTR - X-ray MuPIT 1TYR - X-ray 1TZ8 - X-ray MuPIT 1U21 - X-ray MuPIT 1X7S - X-ray MuPIT 1X7T - X-ray MuPIT 1Y1D - X-ray MuPIT 1Z7J - X-ray 1ZCR - X-ray MuPIT 1ZD6 - X-ray MuPIT 2B14 - X-ray MuPIT 2B15 - X-ray MuPIT 2B16 - X-ray MuPIT 2B77 - X-ray MuPIT 2B9A - X-ray MuPIT 2F7I - X-ray MuPIT 2F8I - X-ray MuPIT 2FBR - X-ray MuPIT 2FLM - X-ray MuPIT 2G3X - X-ray MuPIT 2G3Z - X-ray MuPIT 2G4E - X-ray MuPIT 2G4G - X-ray MuPIT 2G5U - X-ray MuPIT 2G9K - X-ray MuPIT 2GAB - X-ray MuPIT 2H4E - X-ray MuPIT 2NOY - X-ray MuPIT 2PAB - X-ray MuPIT 2QEL - X-ray MuPIT 2QGB - X-ray MuPIT 2QGC - X-ray MuPIT 2QGD - X-ray MuPIT 2QGE - X-ray MuPIT 2ROX - X-ray 2ROY - X-ray 2TRH - X-ray MuPIT 2TRY - X-ray MuPIT 2WQA - X-ray MuPIT 3A4D - X-ray MuPIT 3A4E - X-ray MuPIT 3A4F - X-ray MuPIT 3B56 - X-ray MuPIT 3BSZ - X-ray MuPIT 3BT0 - X-ray MuPIT 3CBR - X-ray MuPIT 3CFM - X-ray MuPIT 3CFN - X-ray MuPIT 3CFQ - X-ray MuPIT 3CFT - X-ray MuPIT 3CN0 - X-ray MuPIT 3CN1 - X-ray MuPIT 3CN2 - X-ray MuPIT 3CN3 - X-ray MuPIT 3CN4 - X-ray MuPIT 3CXF - X-ray MuPIT 3D2T - X-ray MuPIT 3D7P - X-ray MuPIT 3DGD - X-ray MuPIT 3DID - X-ray MuPIT 3DJR - X-ray MuPIT 3DJS - X-ray MuPIT 3DJT - X-ray MuPIT 3DJZ - X-ray MuPIT 3DK0 - X-ray MuPIT 3DK2 - X-ray MuPIT 3DO4 - X-ray MuPIT 3ESN - X-ray MuPIT 3ESO - X-ray MuPIT 3ESP - X-ray MuPIT 3FC8 - X-ray MuPIT 3FCB - X-ray MuPIT 3GLZ - X-ray MuPIT 3GPS - X-ray MuPIT 3GRB - X-ray MuPIT 3GRG - X-ray MuPIT 3GS0 - X-ray MuPIT 3GS4 - X-ray MuPIT 3GS7 - X-ray MuPIT 3HJ0 - X-ray MuPIT 3I9A - X-ray MuPIT 3I9I - X-ray MuPIT 3I9P - X-ray MuPIT 3IMR - X-ray MuPIT 3IMS - X-ray MuPIT 3IMT - X-ray MuPIT 3IMU - X-ray MuPIT 3IMV - X-ray MuPIT 3IMW - X-ray MuPIT 3IPB - X-ray 3IPE - X-ray 3KGS - X-ray MuPIT 3KGT - X-ray MuPIT 3KGU - X-ray MuPIT 3M1O - X-ray MuPIT 3NEE - X-ray MuPIT 3NEO - X-ray MuPIT 3NES - X-ray MuPIT 3NEX - X-ray MuPIT 3NG5 - X-ray MuPIT 3OZK - X-ray MuPIT 3OZL - X-ray MuPIT 3P3R - X-ray MuPIT 3P3S - X-ray MuPIT 3P3T - X-ray MuPIT 3P3U - X-ray MuPIT 3SSG - X-ray MuPIT 3TCT - X-ray MuPIT 3TFB - X-ray MuPIT 3U2I - X-ray MuPIT 3U2J - Neutron MuPIT 4ABQ - X-ray MuPIT 4ABU - X-ray MuPIT 4ABV - X-ray MuPIT 4ABW - X-ray MuPIT 4AC2 - X-ray MuPIT 4ANK - X-ray MuPIT 5TTR - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P02766
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologGenome BrowserNo ortholog
Gene DetailsGene Details  Gene Details 
Gene SorterGene Sorter  Gene Sorter 
 RGDEnsembl WormBase 
    Protein Sequence 
    Alignment 

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0005179 hormone activity
GO:0005515 protein binding
GO:0042562 hormone binding
GO:0042802 identical protein binding
GO:0046982 protein heterodimerization activity
GO:0070324 thyroid hormone binding

Biological Process:
GO:0001523 retinoid metabolic process
GO:0010469 regulation of receptor activity
GO:0030198 extracellular matrix organization
GO:0042572 retinol metabolic process
GO:0043312 neutrophil degranulation
GO:0044267 cellular protein metabolic process
GO:0070327 thyroid hormone transport
GO:0006144 purine nucleobase metabolic process

Cellular Component:
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0005737 cytoplasm
GO:0032991 macromolecular complex
GO:0035578 azurophil granule lumen
GO:0070062 extracellular exosome


-  Descriptions from all associated GenBank mRNAs
  JA482083 - Sequence 66 from Patent WO2011072091.
JE980375 - Sequence 66 from Patent EP2862929.
AK312051 - Homo sapiens cDNA, FLJ92332, Homo sapiens transthyretin (prealbumin, amyloidosis type I) (TTR),mRNA.
E00722 - cDNA lnueding pre-albumin of human liver.
BC005310 - Homo sapiens transthyretin, mRNA (cDNA clone MGC:12385 IMAGE:4071761), complete cds.
GU727633 - Homo sapiens epididymis tissue sperm binding protein Li 4a mRNA, complete cds.
D00096 - Homo sapiens mRNA for prealbumin, complete cds.
K02091 - Human prealbumin mRNA, complete cds.
E01963 - DNA encoding prealbumin.
BC020791 - Homo sapiens transthyretin, mRNA (cDNA clone MGC:23689 IMAGE:4734010), complete cds.
M10605 - Human prealbumin mRNA, complete cds.
X59498 - H.sapiens ttr mRNA for transthyretin.
LG043851 - KR 1020150007359-A/779: Compositions and methods for inhibiting expression of transthyretin.
LG044131 - KR 1020150007359-A/1059: Compositions and methods for inhibiting expression of transthyretin.
LY339507 - KR 1020160079921-A/779: Compositions and methods for inhibiting expression of transthyretin.
LY339787 - KR 1020160079921-A/1059: Compositions and methods for inhibiting expression of transthyretin.
LG043639 - KR 1020150007359-A/567: Compositions and methods for inhibiting expression of transthyretin.
LG043919 - KR 1020150007359-A/847: Compositions and methods for inhibiting expression of transthyretin.
LY339295 - KR 1020160079921-A/567: Compositions and methods for inhibiting expression of transthyretin.
LY339575 - KR 1020160079921-A/847: Compositions and methods for inhibiting expression of transthyretin.
LG043649 - KR 1020150007359-A/577: Compositions and methods for inhibiting expression of transthyretin.
LG043929 - KR 1020150007359-A/857: Compositions and methods for inhibiting expression of transthyretin.
LY339305 - KR 1020160079921-A/577: Compositions and methods for inhibiting expression of transthyretin.
LY339585 - KR 1020160079921-A/857: Compositions and methods for inhibiting expression of transthyretin.
AF162690 - Homo sapiens transthyretin precursor, mRNA, complete cds.
LG043669 - KR 1020150007359-A/597: Compositions and methods for inhibiting expression of transthyretin.
LG043949 - KR 1020150007359-A/877: Compositions and methods for inhibiting expression of transthyretin.
LY339325 - KR 1020160079921-A/597: Compositions and methods for inhibiting expression of transthyretin.
LY339605 - KR 1020160079921-A/877: Compositions and methods for inhibiting expression of transthyretin.
CR456908 - Homo sapiens full open reading frame cDNA clone RZPDo834B067D for gene TTR, transthyretin (prealbumin, amyloidosis type I); complete cds, incl. stopcodon.
BT007189 - Homo sapiens transthyretin (prealbumin, amyloidosis type I) mRNA, complete cds.
JF432547 - Synthetic construct Homo sapiens clone IMAGE:100073771 transthyretin (TTR) gene, encodes complete protein.
KJ892330 - Synthetic construct Homo sapiens clone ccsbBroadEn_01724 TTR gene, encodes complete protein.
KR710754 - Synthetic construct Homo sapiens clone CCSBHm_00016740 TTR (TTR) mRNA, encodes complete protein.
KR710755 - Synthetic construct Homo sapiens clone CCSBHm_00016751 TTR (TTR) mRNA, encodes complete protein.
KR710756 - Synthetic construct Homo sapiens clone CCSBHm_00016813 TTR (TTR) mRNA, encodes complete protein.
KR710757 - Synthetic construct Homo sapiens clone CCSBHm_00016831 TTR (TTR) mRNA, encodes complete protein.
DQ778081 - Homo sapiens clone BFC06100 transthyretin mRNA, complete cds.
DQ839490 - Homo sapiens clone BFC06109 transthyretin mRNA, complete cds.
E01961 - DNA encoding prealbumin.
EU794670 - Homo sapiens epididymis luminal protein 111 (HEL111) mRNA, complete cds.
U19780 - Homo sapiens transthyretin precursor, mRNA, complete cds.
LG043887 - KR 1020150007359-A/815: Compositions and methods for inhibiting expression of transthyretin.
LG044167 - KR 1020150007359-A/1095: Compositions and methods for inhibiting expression of transthyretin.
LY339543 - KR 1020160079921-A/815: Compositions and methods for inhibiting expression of transthyretin.
LY339823 - KR 1020160079921-A/1095: Compositions and methods for inhibiting expression of transthyretin.
LG043803 - KR 1020150007359-A/731: Compositions and methods for inhibiting expression of transthyretin.
LG044083 - KR 1020150007359-A/1011: Compositions and methods for inhibiting expression of transthyretin.
LY339459 - KR 1020160079921-A/731: Compositions and methods for inhibiting expression of transthyretin.
LY339739 - KR 1020160079921-A/1011: Compositions and methods for inhibiting expression of transthyretin.
LG043807 - KR 1020150007359-A/735: Compositions and methods for inhibiting expression of transthyretin.
LG044087 - KR 1020150007359-A/1015: Compositions and methods for inhibiting expression of transthyretin.
LY339463 - KR 1020160079921-A/735: Compositions and methods for inhibiting expression of transthyretin.
LY339743 - KR 1020160079921-A/1015: Compositions and methods for inhibiting expression of transthyretin.
LG043827 - KR 1020150007359-A/755: Compositions and methods for inhibiting expression of transthyretin.
LG044107 - KR 1020150007359-A/1035: Compositions and methods for inhibiting expression of transthyretin.
LY339483 - KR 1020160079921-A/755: Compositions and methods for inhibiting expression of transthyretin.
LY339763 - KR 1020160079921-A/1035: Compositions and methods for inhibiting expression of transthyretin.
LG043905 - KR 1020150007359-A/833: Compositions and methods for inhibiting expression of transthyretin.
LG044185 - KR 1020150007359-A/1113: Compositions and methods for inhibiting expression of transthyretin.
LY339561 - KR 1020160079921-A/833: Compositions and methods for inhibiting expression of transthyretin.
LY339841 - KR 1020160079921-A/1113: Compositions and methods for inhibiting expression of transthyretin.
LG043909 - KR 1020150007359-A/837: Compositions and methods for inhibiting expression of transthyretin.
LG044189 - KR 1020150007359-A/1117: Compositions and methods for inhibiting expression of transthyretin.
LY339565 - KR 1020160079921-A/837: Compositions and methods for inhibiting expression of transthyretin.
LY339845 - KR 1020160079921-A/1117: Compositions and methods for inhibiting expression of transthyretin.
E01962 - DNA encoding prealbumin.
LG043861 - KR 1020150007359-A/789: Compositions and methods for inhibiting expression of transthyretin.
LG044141 - KR 1020150007359-A/1069: Compositions and methods for inhibiting expression of transthyretin.
LY339517 - KR 1020160079921-A/789: Compositions and methods for inhibiting expression of transthyretin.
LY339797 - KR 1020160079921-A/1069: Compositions and methods for inhibiting expression of transthyretin.
LG043633 - KR 1020150007359-A/561: Compositions and methods for inhibiting expression of transthyretin.
LG043913 - KR 1020150007359-A/841: Compositions and methods for inhibiting expression of transthyretin.
LY339289 - KR 1020160079921-A/561: Compositions and methods for inhibiting expression of transthyretin.
LY339569 - KR 1020160079921-A/841: Compositions and methods for inhibiting expression of transthyretin.
LG043875 - KR 1020150007359-A/803: Compositions and methods for inhibiting expression of transthyretin.
LG044155 - KR 1020150007359-A/1083: Compositions and methods for inhibiting expression of transthyretin.
LY339531 - KR 1020160079921-A/803: Compositions and methods for inhibiting expression of transthyretin.
LY339811 - KR 1020160079921-A/1083: Compositions and methods for inhibiting expression of transthyretin.
M11714 - Human transthyretin mRNA, partial cds.
LG043879 - KR 1020150007359-A/807: Compositions and methods for inhibiting expression of transthyretin.
LG044159 - KR 1020150007359-A/1087: Compositions and methods for inhibiting expression of transthyretin.
LY339535 - KR 1020160079921-A/807: Compositions and methods for inhibiting expression of transthyretin.
LY339815 - KR 1020160079921-A/1087: Compositions and methods for inhibiting expression of transthyretin.
LG043657 - KR 1020150007359-A/585: Compositions and methods for inhibiting expression of transthyretin.
LG043937 - KR 1020150007359-A/865: Compositions and methods for inhibiting expression of transthyretin.
LY339313 - KR 1020160079921-A/585: Compositions and methods for inhibiting expression of transthyretin.
LY339593 - KR 1020160079921-A/865: Compositions and methods for inhibiting expression of transthyretin.
LG043659 - KR 1020150007359-A/587: Compositions and methods for inhibiting expression of transthyretin.
LG043939 - KR 1020150007359-A/867: Compositions and methods for inhibiting expression of transthyretin.
LY339315 - KR 1020160079921-A/587: Compositions and methods for inhibiting expression of transthyretin.
LY339595 - KR 1020160079921-A/867: Compositions and methods for inhibiting expression of transthyretin.
LG043683 - KR 1020150007359-A/611: Compositions and methods for inhibiting expression of transthyretin.
LG043963 - KR 1020150007359-A/891: Compositions and methods for inhibiting expression of transthyretin.
LY339339 - KR 1020160079921-A/611: Compositions and methods for inhibiting expression of transthyretin.
LY339619 - KR 1020160079921-A/891: Compositions and methods for inhibiting expression of transthyretin.
LG043695 - KR 1020150007359-A/623: Compositions and methods for inhibiting expression of transthyretin.
LG043975 - KR 1020150007359-A/903: Compositions and methods for inhibiting expression of transthyretin.
LY339351 - KR 1020160079921-A/623: Compositions and methods for inhibiting expression of transthyretin.
LY339631 - KR 1020160079921-A/903: Compositions and methods for inhibiting expression of transthyretin.
LG043711 - KR 1020150007359-A/639: Compositions and methods for inhibiting expression of transthyretin.
LG043991 - KR 1020150007359-A/919: Compositions and methods for inhibiting expression of transthyretin.
LY339367 - KR 1020160079921-A/639: Compositions and methods for inhibiting expression of transthyretin.
LY339647 - KR 1020160079921-A/919: Compositions and methods for inhibiting expression of transthyretin.
LG043739 - KR 1020150007359-A/667: Compositions and methods for inhibiting expression of transthyretin.
LG044019 - KR 1020150007359-A/947: Compositions and methods for inhibiting expression of transthyretin.
LY339395 - KR 1020160079921-A/667: Compositions and methods for inhibiting expression of transthyretin.
LY339675 - KR 1020160079921-A/947: Compositions and methods for inhibiting expression of transthyretin.
LG043763 - KR 1020150007359-A/691: Compositions and methods for inhibiting expression of transthyretin.
LG044043 - KR 1020150007359-A/971: Compositions and methods for inhibiting expression of transthyretin.
LY339419 - KR 1020160079921-A/691: Compositions and methods for inhibiting expression of transthyretin.
LY339699 - KR 1020160079921-A/971: Compositions and methods for inhibiting expression of transthyretin.
LG043765 - KR 1020150007359-A/693: Compositions and methods for inhibiting expression of transthyretin.
LG044045 - KR 1020150007359-A/973: Compositions and methods for inhibiting expression of transthyretin.
LY339421 - KR 1020160079921-A/693: Compositions and methods for inhibiting expression of transthyretin.
LY339701 - KR 1020160079921-A/973: Compositions and methods for inhibiting expression of transthyretin.
LG043767 - KR 1020150007359-A/695: Compositions and methods for inhibiting expression of transthyretin.
LG044047 - KR 1020150007359-A/975: Compositions and methods for inhibiting expression of transthyretin.
LY339423 - KR 1020160079921-A/695: Compositions and methods for inhibiting expression of transthyretin.
LY339703 - KR 1020160079921-A/975: Compositions and methods for inhibiting expression of transthyretin.
LG043775 - KR 1020150007359-A/703: Compositions and methods for inhibiting expression of transthyretin.
LG044055 - KR 1020150007359-A/983: Compositions and methods for inhibiting expression of transthyretin.
LY339431 - KR 1020160079921-A/703: Compositions and methods for inhibiting expression of transthyretin.
LY339711 - KR 1020160079921-A/983: Compositions and methods for inhibiting expression of transthyretin.
LG043781 - KR 1020150007359-A/709: Compositions and methods for inhibiting expression of transthyretin.
LG044061 - KR 1020150007359-A/989: Compositions and methods for inhibiting expression of transthyretin.
LY339437 - KR 1020160079921-A/709: Compositions and methods for inhibiting expression of transthyretin.
LY339717 - KR 1020160079921-A/989: Compositions and methods for inhibiting expression of transthyretin.
JD208012 - Sequence 189036 from Patent EP1572962.
LG044408 - KR 1020150007359-A/1336: Compositions and methods for inhibiting expression of transthyretin.
LY340064 - KR 1020160079921-A/1336: Compositions and methods for inhibiting expression of transthyretin.
LG044412 - KR 1020150007359-A/1340: Compositions and methods for inhibiting expression of transthyretin.
LY340068 - KR 1020160079921-A/1340: Compositions and methods for inhibiting expression of transthyretin.
LG044414 - KR 1020150007359-A/1342: Compositions and methods for inhibiting expression of transthyretin.
LY340070 - KR 1020160079921-A/1342: Compositions and methods for inhibiting expression of transthyretin.
LG043799 - KR 1020150007359-A/727: Compositions and methods for inhibiting expression of transthyretin.
LG044079 - KR 1020150007359-A/1007: Compositions and methods for inhibiting expression of transthyretin.
LG044422 - KR 1020150007359-A/1350: Compositions and methods for inhibiting expression of transthyretin.
LY339455 - KR 1020160079921-A/727: Compositions and methods for inhibiting expression of transthyretin.
LY339735 - KR 1020160079921-A/1007: Compositions and methods for inhibiting expression of transthyretin.
LY340078 - KR 1020160079921-A/1350: Compositions and methods for inhibiting expression of transthyretin.
LG043801 - KR 1020150007359-A/729: Compositions and methods for inhibiting expression of transthyretin.
LG044081 - KR 1020150007359-A/1009: Compositions and methods for inhibiting expression of transthyretin.
LG044480 - KR 1020150007359-A/1408: Compositions and methods for inhibiting expression of transthyretin.
LY339457 - KR 1020160079921-A/729: Compositions and methods for inhibiting expression of transthyretin.
LY339737 - KR 1020160079921-A/1009: Compositions and methods for inhibiting expression of transthyretin.
LY340136 - KR 1020160079921-A/1408: Compositions and methods for inhibiting expression of transthyretin.
LG044424 - KR 1020150007359-A/1352: Compositions and methods for inhibiting expression of transthyretin.
LY340080 - KR 1020160079921-A/1352: Compositions and methods for inhibiting expression of transthyretin.
LG044426 - KR 1020150007359-A/1354: Compositions and methods for inhibiting expression of transthyretin.
LY340082 - KR 1020160079921-A/1354: Compositions and methods for inhibiting expression of transthyretin.
LG044428 - KR 1020150007359-A/1356: Compositions and methods for inhibiting expression of transthyretin.
LY340084 - KR 1020160079921-A/1356: Compositions and methods for inhibiting expression of transthyretin.
LG044450 - KR 1020150007359-A/1378: Compositions and methods for inhibiting expression of transthyretin.
LY340106 - KR 1020160079921-A/1378: Compositions and methods for inhibiting expression of transthyretin.
LG044454 - KR 1020150007359-A/1382: Compositions and methods for inhibiting expression of transthyretin.
LY340110 - KR 1020160079921-A/1382: Compositions and methods for inhibiting expression of transthyretin.
LG044456 - KR 1020150007359-A/1384: Compositions and methods for inhibiting expression of transthyretin.
LY340112 - KR 1020160079921-A/1384: Compositions and methods for inhibiting expression of transthyretin.
LG044458 - KR 1020150007359-A/1386: Compositions and methods for inhibiting expression of transthyretin.
LY340114 - KR 1020160079921-A/1386: Compositions and methods for inhibiting expression of transthyretin.
LG044460 - KR 1020150007359-A/1388: Compositions and methods for inhibiting expression of transthyretin.
LY340116 - KR 1020160079921-A/1388: Compositions and methods for inhibiting expression of transthyretin.
LG044470 - KR 1020150007359-A/1398: Compositions and methods for inhibiting expression of transthyretin.
LY340126 - KR 1020160079921-A/1398: Compositions and methods for inhibiting expression of transthyretin.
LG044476 - KR 1020150007359-A/1404: Compositions and methods for inhibiting expression of transthyretin.
LY340132 - KR 1020160079921-A/1404: Compositions and methods for inhibiting expression of transthyretin.
LG043811 - KR 1020150007359-A/739: Compositions and methods for inhibiting expression of transthyretin.
LG044091 - KR 1020150007359-A/1019: Compositions and methods for inhibiting expression of transthyretin.
LY339467 - KR 1020160079921-A/739: Compositions and methods for inhibiting expression of transthyretin.
LY339747 - KR 1020160079921-A/1019: Compositions and methods for inhibiting expression of transthyretin.
LG043815 - KR 1020150007359-A/743: Compositions and methods for inhibiting expression of transthyretin.
LG044095 - KR 1020150007359-A/1023: Compositions and methods for inhibiting expression of transthyretin.
LY339471 - KR 1020160079921-A/743: Compositions and methods for inhibiting expression of transthyretin.
LY339751 - KR 1020160079921-A/1023: Compositions and methods for inhibiting expression of transthyretin.
JD110725 - Sequence 91749 from Patent EP1572962.

-  Biochemical and Signaling Pathways
  Reactome (by CSHL, EBI, and GO)

Protein P02766 (Reactome details) participates in the following event(s):

R-HSA-2404134 RBP4:atROL binds TTR
R-HSA-6798751 Exocytosis of azurophil granule lumen proteins
R-HSA-2396337 HSPG2 binds FGF2(10-155), Fibronectn matrix, Transthyretin tetramer, PDGFA homodimer, PDGFB homodimer
R-HSA-2453876 TTR:RBP:atROL binds to STRA6 receptor
R-HSA-2453863 STRA6 transports atROL from extracellular region to cytosol
R-HSA-975634 Retinoid metabolism and transport
R-HSA-6798695 Neutrophil degranulation
R-HSA-3000171 Non-integrin membrane-ECM interactions
R-HSA-2453902 The canonical retinoid cycle in rods (twilight vision)
R-HSA-2187338 Visual phototransduction
R-HSA-6806667 Metabolism of fat-soluble vitamins
R-HSA-977225 Amyloid fiber formation
R-HSA-168249 Innate Immune System
R-HSA-1474244 Extracellular matrix organization
R-HSA-2453864 Retinoid cycle disease events
R-HSA-418594 G alpha (i) signalling events
R-HSA-196854 Metabolism of vitamins and cofactors
R-HSA-392499 Metabolism of proteins
R-HSA-168256 Immune System
R-HSA-2474795 Diseases associated with visual transduction
R-HSA-388396 GPCR downstream signalling
R-HSA-1430728 Metabolism
R-HSA-5663202 Diseases of signal transduction
R-HSA-372790 Signaling by GPCR
R-HSA-1643685 Disease
R-HSA-162582 Signal Transduction

-  Other Names for This Gene
  Alternate Gene Symbols: ENST00000237014.1, ENST00000237014.2, ENST00000237014.3, ENST00000237014.4, ENST00000237014.5, ENST00000237014.6, ENST00000237014.7, NM_000371, P02766, PALB, Q549C7, Q6IB96, Q9UBZ6, Q9UCM9, TTHY_HUMAN, uc317ebv.1, uc317ebv.2
UCSC ID: ENST00000237014.8_4
RefSeq Accession: NM_000371.4
Protein: P02766 (aka TTHY_HUMAN)

-  GeneReviews for This Gene
  GeneReviews article(s) related to gene TTR:
tfap (Hereditary Transthyretin Amyloidosis)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.